S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
S&P 500   5,251.59 (+0.06%)
DOW   39,764.85 (+0.01%)
QQQ   444.25 (-0.13%)
AAPL   171.20 (-1.22%)
MSFT   419.89 (-0.37%)
META   486.02 (-1.59%)
GOOGL   150.66 (-0.14%)
AMZN   179.92 (+0.05%)
TSLA   177.64 (-1.22%)
NVDA   907.63 (+0.57%)
NIO   4.61 (-1.28%)
AMD   182.03 (+1.36%)
BABA   72.47 (+1.23%)
T   17.61 (+0.34%)
F   13.21 (+1.15%)
MU   118.10 (-0.87%)
CGC   9.78 (+2.41%)
GE   175.38 (-2.63%)
DIS   122.58 (+1.32%)
AMC   3.70 (-14.75%)
PFE   27.91 (+0.47%)
PYPL   67.53 (+1.44%)
XOM   115.75 (+0.68%)
NYSE:GKOS

Glaukos (GKOS) Stock Price, News & Analysis

$93.04
+0.35 (+0.38%)
(As of 12:36 PM ET)
Today's Range
$92.29
$93.57
50-Day Range
$84.31
$96.42
52-Week Range
$45.38
$97.24
Volume
81,254 shs
Average Volume
701,908 shs
Market Capitalization
$4.60 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$96.30

Glaukos MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.78 Rating Score
Upside/​Downside
3.1% Upside
$96.30 Price Target
Short Interest
Bearish
7.40% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.33mentions of Glaukos in the last 14 days
Based on 14 Articles This Week
Insider Trading
Selling Shares
$22.11 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.67 out of 5 stars

Medical Sector

465th out of 939 stocks

Surgical & Medical Instruments Industry

54th out of 98 stocks

GKOS stock logo

About Glaukos Stock (NYSE:GKOS)

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.

GKOS Stock Price History

GKOS Stock News Headlines

Glaukos (NYSE:GKOS) Price Target Raised to $120.00
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
Glaukos (NYSE:GKOS) Trading Up 2.4%
Glaukos (NYSE:GKOS) Receives "Buy" Rating from Truist Financial
Trump’s “Tax Free” Retirement Strategy
Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.
Truist Financial Reaffirms Their Buy Rating on Glaukos (GKOS)
5 Analysts Have This To Say About Glaukos
GKOS Apr 2024 140.000 call
GKOS Apr 2024 92.500 put
GKOS Apr 2024 80.000 put
Glaukos Corp Director Mark Foley Sells 4,560 Shares
Glaukos Stock (NYSE:GKOS), Short Interest Report
GKOS Apr 2024 47.500 put
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/21/2024
Today
3/28/2024
Next Earnings (Estimated)
5/01/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Employees
783
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$96.30
High Stock Price Target
$120.00
Low Stock Price Target
$65.00
Potential Upside/Downside
+3.9%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.78
Research Coverage
9 Analysts

Profitability

Net Income
$-134,660,000.00
Pretax Margin
-42.49%

Debt

Sales & Book Value

Annual Sales
$314.71 million
Book Value
$9.46 per share

Miscellaneous

Free Float
45,611,000
Market Cap
$4.59 billion
Optionable
Optionable
Beta
1.08
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives


GKOS Stock Analysis - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price target for 2024?

9 brokerages have issued twelve-month price objectives for Glaukos' shares. Their GKOS share price targets range from $65.00 to $120.00. On average, they expect the company's stock price to reach $96.30 in the next year. This suggests a possible upside of 3.1% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2024?

Glaukos' stock was trading at $79.49 at the beginning of the year. Since then, GKOS shares have increased by 17.5% and is now trading at $93.38.
View the best growth stocks for 2024 here
.

Are investors shorting Glaukos?

Glaukos saw a decrease in short interest in the month of February. As of February 15th, there was short interest totaling 3,630,000 shares, a decrease of 8.6% from the January 31st total of 3,970,000 shares. Based on an average daily trading volume, of 829,900 shares, the days-to-cover ratio is currently 4.4 days.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings data on Wednesday, February, 21st. The medical instruments supplier reported ($0.63) EPS for the quarter, missing analysts' consensus estimates of ($0.56) by $0.07. The medical instruments supplier had revenue of $82.40 million for the quarter, compared to analyst estimates of $81 million. Glaukos had a negative trailing twelve-month return on equity of 22.67% and a negative net margin of 42.79%. Glaukos's revenue for the quarter was up 15.7% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.53) earnings per share.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2024 earnings guidance on Friday, February, 2nd. The company provided EPS guidance of for the period. The company issued revenue guidance of $350.0 million-$360.0 million, compared to the consensus revenue estimate of $352.7 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

Glaukos (GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs acted as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

Who are Glaukos' major shareholders?

Glaukos' stock is owned by many different retail and institutional investors. Top institutional investors include Vanguard Group Inc. (10.73%), Vanguard Group Inc. (10.59%), Brown Capital Management LLC (5.53%), Wellington Management Group LLP (2.71%), Artisan Partners Limited Partnership (2.51%) and Dimensional Fund Advisors LP (1.89%). Insiders that own company stock include Alex R Thurman, Gilbert H Kliman, Joseph E Gilliam, Joseph E Gilliam, Marc Stapley, Mark J Foley and Thomas William Burns.
View institutional ownership trends
.

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NYSE:GKOS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners